Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus

NCT01245166 is registered in ClinicalTrials.gov with Lotus Pharmaceutical as lead sponsor.

NCT NCT01245166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01245166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus
Lead sponsor
Lotus Pharmaceutical
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2010
Completion date
December 31, 2011
Enrollment
220 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plus acarbose 50 mg tablets) thrice daily versus acarbose 50 mg thrice daily over 16 weeks in, subjects with type 2 diabetes mellitus., the objectives of the study is to evaluate the efficacy and safety of acarmet (metformin hcl 500 mg